Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2024 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
February 22, 2024 07:30 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update

Full year 2023 total revenues of $464.4 million, compared to $250.3 million in 2022 Full year 2023 CAPLYTA net product sales were $462.2 million, representing year-over-year growth of 86%. CAPLYTA...
February 08, 2024 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
January 02, 2024 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
December 05, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting

Company presents positive results of a pre-specified patient population in Study 403 examining the effects of CAPLYTA® (lumateperone) in patients experiencing a major depressive episode with anxious...
November 15, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
November 02, 2023 07:30 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

Q3 2023 total revenues increased to $126.2 million, compared to $71.9 million in the same period in 2022 CAPLYTA Q3 2023 net product sales were $125.8 million, compared to $71.9 million for the...
October 31, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
October 26, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast

NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
September 20, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...